Study guide

9.3 Men's Health: Benign Prostatic Hyperplasia, Prostatitis, Epididymitis & Erectile Dysfunction

ANCC Adult-Gerontology Primary Care Nurse Practitioner AGPCNP-BC

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: The AGPCNP-BC Examination: Blueprint, Format & Scoring

1.1 The AGPCNP-BC Blueprint, Exam Format, Scoring, Eligibility & Renewal

2 Chapter 2: Assessment Foundations & Lifespan Considerations

2.1 Comprehensive Health History, Symptom Analysis & Lifespan Variations 2.2 Physical Examination Techniques & Age-Related Physiological Changes 2.3 Functional Assessment (Katz ADL / Lawton IADL) & Frailty Syndromes 2.4 Psychosocial, Nutritional, Cognitive & Mental Health Screening Instruments 2.5 Health Screening Guidelines (USPSTF) & Adult Immunization Schedules (CDC/ACIP)

3 Chapter 3: Diagnostic Reasoning & Clinical Interpretation

3.1 Diagnostic Reasoning, Clinical Decision-Making & Differential Diagnosis Formulation 3.2 Routine & Specialized Laboratory Interpretation 3.3 Diagnostic Imaging, ECG Interpretation & Pulmonary Function Testing 3.4 Evidence-Based Testing, Pre-Test Probability & Choosing Wisely Principles

4 Chapter 4: Cardiovascular Disorders

4.1 Hypertension: 2025 AHA/ACC Guideline, Resistant HTN & Secondary HTN 4.2 Dyslipidemia & ASCVD Risk Calculation, Statin Therapy & Non-Statin Agents 4.3 Coronary Artery Disease, Stable Angina & Post-ACS Outpatient Management 4.4 Heart Failure (HFrEF/HFpEF), Atrial Fibrillation & Peripheral Vascular Disease

5 Chapter 5: Respiratory Disorders

5.1 Asthma: GINA 2026 Guidelines, Phenotypes, Stepwise Pharmacotherapy & Action Plans 5.2 COPD: GOLD 2026 Report, ABE Staging, Triple Inhalers & Exacerbations 5.3 Lower Respiratory Infections (CAP, Bronchitis), Pleural Disease & Solitary Pulmonary Nodules

6 Chapter 6: HEENT & Allergic/Immunologic Disorders

6.1 Eye & Vision Disorders in Adult-Gerontology Primary Care 6.2 Ear, Hearing & Vestibular Disorders 6.3 Nose, Sinus, Oropharyngeal & Oral Cavity Disorders 6.4 Allergic & Immunologic Disorders: Anaphylaxis, Urticaria, Angioedema & Immunodeficiency

7 Chapter 7: Endocrine & Metabolic Disorders

7.1 Type 2 Diabetes Mellitus: ADA Standards of Care, Pharmacotherapy & Microvascular Complications 7.2 Thyroid Disorders: Hypothyroidism, Hyperthyroidism, Thyroiditis & Nodules 7.3 Adrenal & Pituitary Disorders: Adrenal Insufficiency, Cushing's, Hyperaldosteronism & Hypopituitarism 7.4 Metabolic Bone Disease: Osteopenia, Osteoporosis (FRAX, DEXA) & Hyperparathyroidism

8 Chapter 8: Gastrointestinal & Hepatic Disorders

8.1 Upper GI Disorders: GERD, Barrett's Esophagus, PUD, H. pylori & Gastritis 8.2 Lower GI Disorders: Irritable Bowel Syndrome (IBS), Inflammatory Bowel Disease (IBD) & Diverticular Disease 8.3 Hepatobiliary Disorders: MASLD/MASH, Viral & Alcoholic Hepatitis, Cirrhosis & Cholelithiasis 8.4 Acute & Chronic Abdominal Pain Syndromes, GI Bleeding & Colorectal Cancer Screening

9 Chapter 9: Renal, Urological & Men's Health

9.1 Chronic Kidney Disease: KDIGO Staging, Albuminuria Management & Renoprotective Strategies 9.2 Urinary Tract Infections (Uncomplicated, Complicated, Recurrent), Pyelonephritis & Microscopic Hematuria 9.3 Men's Health: Benign Prostatic Hyperplasia, Prostatitis, Epididymitis & Erectile Dysfunction

10 Chapter 10: Musculoskeletal & Rheumatologic Disorders

10.1 Degenerative & Overuse Musculoskeletal Disorders: Osteoarthritis, Tendinopathies & Spine Disorders 10.2 Autoimmune Rheumatologic Disorders: Rheumatoid Arthritis, SLE, Polymyalgia Rheumatica & Giant Cell Arteritis 10.3 Crystal Arthropathies & Fibromyalgia: Gout, Pseudogout & Centralized Pain Syndromes

11 Chapter 11: Neurological & Psychiatric Disorders

11.1 Headaches (Migraine, Tension, Cluster) & Cranial Neuralgias 11.2 Cerebrovascular Disease, TIA, Peripheral Neuropathies & Movement Disorders (Parkinson's) 11.3 Mood & Anxiety Disorders: Major Depressive Disorder, Generalized Anxiety Disorder & PTSD 11.4 Substance Use Disorders: Alcohol, Tobacco, Opioids & Cannabis in Primary Care

12 Chapter 12: Dermatologic, Hematologic & Infectious Disease

12.1 Primary Dermatologic Lesions, Inflammatory Dermatoses & Cutaneous Malignancies 12.2 Common Infectious Diseases: Skin/Soft Tissue Infections, Tick-Borne Illnesses & Viral Syndromes 12.3 Sexually Transmitted Infections (STIs): CDC Guidelines, Screening & Partner Management 12.4 Hematologic Disorders: Anemias (Microcytic, Normocytic, Macrocytic), Leukopenia & Coagulopathies

13 Chapter 13: Geriatric Syndromes, Pharmacology & Palliative Care

13.1 The Geriatric 5Ms Framework, Multimorbidity & Polypharmacy Deprescribing 13.2 Beers Criteria 2023 Update & STOPP/START Prescribing Rules 13.3 Pharmacokinetics, Pharmacodynamics & Pharmacogenomics Across the Adult Lifespan 13.4 Dementia vs. Delirium vs. Depression: Differential Diagnostics & Management 13.5 Falls, Mobility Impairment, Pressure Injury Prevention & Palliative Care Transitions

14 Chapter 14: Gynecologic & Women's Health

14.1 Contraceptive Management, Emergency Contraception & Preconception Counseling 14.2 Perimenopause, Menopause & Hormone Replacement Therapy (HRT) 14.3 Gynecologic Infections (Vaginitis, PID), Abnormal Uterine Bleeding & Cervical Cancer Screening (USPSTF/ASCCP)

15 Chapter 15: Plan-of-Care Process: Behavior Change, Education & Care Coordination

15.1 Behavioral Change: Motivational Interviewing, Models & Theories 15.2 Patient Education, Shared Decision-Making, Referrals, Care Coordination & Plan Reassessment

16 Chapter 16: APRN Professional Practice, Ethics, Policy & Quality Improvement

16.1 APRN Scope of Practice, Consensus Model, Collaborative Practice & Credentialing 16.2 Bioethics, Informed Consent, Advance Directives & Surrogate Decision-Making 16.3 Environmental & Social Determinants of Health, Health Equity & Culturally Responsive Care 16.4 Evidence-Based Practice (EBP), Quality Improvement (QI) Methodologies & Healthcare Economics

9.3 Men's Health: Benign Prostatic Hyperplasia, Prostatitis, Epididymitis & Erectile Dysfunction

Key Takeaways Explain This Topic AI

Benign Prostatic Hyperplasia (BPH) arises from DHT-driven stromal and glandular proliferation in the transition (periurethral) zone; first-line medical therapy utilizes uroselective Alpha-1 Adrenergic Antagonists (e.g., Tamsulosin) for rapid dynamic symptom relief, while 5-Alpha Reductase Inhibitors (5-ARIs: Finasteride, Dutasteride) induce static shrinkage of enlarged prostates (>30 g).

5-Alpha Reductase Inhibitors decrease serum PSA levels by ~50% after 6 months; providers must multiply the measured PSA by 2 (double the value) to establish the true baseline when screening for prostate adenocarcinoma.

Acute Bacterial Prostatitis presents with sudden high fever, chills, perineal pain, and obstructive voiding; on DRE, the prostate is exquisitely tender, warm, and boggy; vigorous prostatic massage is strictly contraindicated due to the high risk of bacteremia and septic shock.

Acute Epididymitis is differentiated from Testicular Torsion by physical examination maneuvers: Epididymitis features a positive Prehn's sign (pain relief with scrotal elevation) and a preserved cremasteric reflex, whereas Testicular Torsion exhibits a negative Prehn's sign, absent cremasteric reflex, and requires immediate emergency surgical detorsion.

PDE5 Inhibitors (Sildenafil, Tadalafil) are first-line for Erectile Dysfunction; co-administration with nitrates (nitroglycerin, isosorbide mononitrate) is ABSOLUTELY CONTRAINDICATED due to massive life-threatening hypotension; patients must separate sildenafil by ≥24 hours and tadalafil by ≥48 hours from nitrate therapy.

Last updated: August 2026

Men's Health: Benign Prostatic Hyperplasia, Prostatitis, Epididymitis & Erectile Dysfunction

Men's urological and reproductive health encompasses a diverse spectrum of acute infectious, chronic obstructive, and vascular-endocrine disorders that significantly impact quality of life and longevity. For the Adult-Gerontology Primary Care Nurse Practitioner (AGPCNP) , board certification mandates expertise in managing Lower Urinary Tract Symptoms (LUTS) secondary to Benign Prostatic Hyperplasia (BPH), understanding the pharmacodynamics and PSA-altering effects of urological drugs, managing acute and chronic prostatitis syndromes while avoiding diagnostic pitfalls, differentiating acute scrotal emergencies (epididymitis vs. testicular torsion), and navigating the comprehensive workup and safe pharmacological management of Erectile Dysfunction (ED).

  • 1. Benign Prostatic Hyperplasia (BPH)
  • Pathophysiology & Anatomical Zonation

BPH is a non-malignant adenomatous proliferation of prostatic epithelial and stromal cells. Intraprostatic 5-Alpha Reductase (Type 2) converts circulating testosterone into Dihydrotestosterone (DHT) , a potent androgen with a 5-fold higher binding affinity for androgen receptors. DHT stimulates transcription of growth factors (FGF, TGF- β \beta β ), driving cellular hyperplasia. +-----------------------------------------------------------------------------+

  • | PROSTATE ANATOMICAL ZONES |
  • | |
  • | 1. TRANSITION ZONE (Periurethral Zone) |
  • | - Surrounds the proximal prostatic urethra (5-10% of prostate volume). |
  • | - SITE OF ORIGIN FOR BENIGN PROSTATIC HYPERPLASIA (BPH). |
  • | - Progressive hyperplasia compresses urethral lumen -> LUTS. |
  • | |
  • | 2. PERIPHERAL ZONE (Posterior & Outer Aspect) |
  • | - Comprises 70% of prostate volume; easily palpable via DRE. |
  • | - SITE OF ORIGIN FOR > 70-80% OF PROSTATE ADENOCARCINOMAS. |
  • | - Palpable induration, nodules, or asymmetry suggest malignancy. |
  • | |
  • | 3. CENTRAL ZONE |
  • | - Surrounds ejaculatory ducts (25% of volume). |
  • +-----------------------------------------------------------------------------+

Clinical Presentation: Storage vs. Voiding LUTS +-----------------------------------------------------------------------------+

  • | LOWER URINARY TRACT SYMPTOMS (LUTS) |
  • | |
  • | STORAGE / IRRITATIVE SYMPTOMS VOIDING / OBSTRUCTIVE SYMPTOMS |
  • | (Secondary to Bladder Response) (Direct Mechanical/Dynamic Block) |
  • | ----------------------------------------------------------------------- |
  • | - Urinary Urgency (sudden need) - Urinary Hesitancy (delayed start) |
  • | - Urinary Frequency (voiding > Q2H) - Weak / Decreased Urinary Stream |
  • | - Nocturia (>= 2 awakenings/night) - Intermittency (stop-start stream) |
  • | - Urge Incontinence (detrusor - Terminal Dribbling |
  • | overactivity / involuntary spasm) - Sensation of Incomplete Emptying |
  • | - Dysuria (irritation) - Straining to Initiate Voiding |
  • +-----------------------------------------------------------------------------+
  • Clinical Evaluation & Diagnostic Workup

International Prostate Symptom Score (IPSS) / AUA Symptom Index:

Standardized 7-question validated questionnaire assessing symptom severity (Score: 0–7 Mild , 8–19 Moderate , 20–35 Severe ) plus a Quality of Life (QoL) bother score.

Digital Rectal Examination (DRE):

Classic BPH finding: Symmetrically enlarged, smooth, firm, elastic, rubbery, non-tender prostate with a preserved median sulcus.

Hard, stony, asymmetrical, discrete nodules, or loss of median sulcus suggest prostate adenocarcinoma mandating serum PSA and urology biopsy referral.

Urinalysis: Dipstick and microscopy to rule out hematuria, pyuria, and urinary tract infection.

Serum Prostate-Specific Antigen (PSA): Quantifies risk of clinical progression, acute urinary retention, and aids in shared decision-making for prostate cancer screening.

Post-Void Residual (PVR) Measurement: Bedside bladder ultrasound immediately after voiding. Normal < 50 mL < 50\text{ mL} < 50 mL ; a PVR > 200 – 300 mL > 200\text{--}300\text{ mL} > 200 – 300 mL indicates significant urinary retention / detrusor failure.

Serum Creatinine: Indicated if urinary retention, hydronephrosis, or obstructive nephropathy is suspected.

Guideline-Directed Pharmacotherapy for BPH +-----------------------------------------------------------------------------+

  • | BPH PHARMACOTHERAPY MATRIX |
  • | |
  • | DRUG CLASS REPRESENTATIVE AGENTS MECHANISM & CLINICAL PEARLS|
  • | ----------------------------------------------------------------------- |
  • | Alpha-1 Adrenergic Tamsulosin (0.4-0.8mg) - Relaxes smooth muscle of |
  • | Antagonists (Uro- Alfuzosin (10 mg daily) bladder neck, prostate |
  • | selective: alpha-1A) Silodosin (8 mg daily) capsule & prostatic ureth|
  • | - RAPID onset (48-72 hours)|
  • | - Does NOT shrink prostate |
  • | - Does NOT change PSA |
  • | - SE: Retrograde ejaculat, |
  • | Intraoperative Floppy |
  • | Iris Syndrome (IFIS). |
  • | |
  • | Alpha-1 Antagonists Doxazosin (Cardura) - Non-selective; causes |
  • | (Non-selective) Terazosin (Hytrin) vasodilation & BP drop |
  • | - SE: First-dose orthostas,|
  • | syncope, dizziness. |
  • | |
  • | 5-Alpha Reductase Finasteride (5 mg daily)- Blocks conversion of |
  • | Inhibitors (5-ARIs) Dutasteride (0.5mg daily) Testosterone -> DHT. |
  • | - Shrinks prostate volume |
  • | by 20-25% over 6-12 mos. |
  • | - Indicated for enlarged |
  • | prostates (> 30-40 grams)|
  • | - HALVES SERUM PSA (-50%)! |
  • | - SE: ED, decreased libido,|
  • | gynecomastia, depression.|
  • | |
  • | PDE5 Inhibitors Tadalafil (5 mg daily) - Increases cGMP in bladder|
  • | & prostate smooth muscle.|
  • | - FDA approved for BPH + ED|
  • | - NEVER mix with nitrates! |
  • +-----------------------------------------------------------------------------+

Important

The Mandatory "PSA Doubling Rule" for 5-ARIs: Chronic therapy with a 5-Alpha Reductase Inhibitor (Finasteride or Dutasteride) shrinks the glandular epithelial component of the prostate and decreases serum PSA levels by approximately 50% after 6 months of continuous use . When interpreting serum PSA in a man who has taken a 5-ARI for ≥ 6 \ge 6 ≥ 6 months, the AGPCNP must multiply the reported laboratory PSA by 2 (double the value) to obtain the patient's true baseline. Any confirmed increase in PSA while taking a 5-ARI (even a rise within "normal" ranges) is abnormal and mandates immediate urological referral to evaluate for high-grade prostate cancer!

Note

Intraoperative Floppy Iris Syndrome (IFIS): Alpha-1 antagonists (especially α 1 A \alpha_{1A} α 1 A ​ -selective agents like Tamsulosin ) block pupillary dilator smooth muscle receptors in the iris. Patients undergoing cataract surgery are at high risk for IFIS (triad of flaccid iris stroma, progressive intraoperative pupillary constriction, and iris prolapse). Patients must inform their ophthalmologist of past or present alpha-blocker exposure prior to eye surgery.

2. Prostatitis Syndromes (NIH Classification)

Prostatitis comprises a collection of infectious and non-infectious inflammatory disorders of the prostate gland classified into four major categories by the National Institutes of Health (NIH). +-----------------------------------------------------------------------------+

  • | NIH CLASSIFICATION OF PROSTATITIS |
  • | |
  • | * Category I: ACUTE BACTERIAL PROSTATITIS (ABP) |
  • | - Acute, severe systemic bacterial infection of prostate. |
  • | |
  • | * Category II: CHRONIC BACTERIAL PROSTATITIS (CBP) |
  • | - Recurrent, relapsing UTIs with same bacterial strain. |
  • | |
  • | * Category III: CHRONIC PROSTATITIS / CHRONIC PELVIC PAIN SYNDROME (CP/CPPS|
  • | - Pelvic pain/discomfort >= 3 months without bacteria. |
  • | - Accounts for > 90% of all prostatitis presentations! |
  • | - IIIa: Inflammatory (WBCs in semen/EPS); IIIb: Non-inflam|
  • | |
  • | * Category IV: ASYMPTOMATIC INFLAMMATORY PROSTATITIS |
  • | - Incidental WBCs in EPS/biopsy without clinical symptoms.|
  • +-----------------------------------------------------------------------------+
  • Acute Bacterial Prostatitis (Category I)

Etiology: Ascending infection of enteric uropathogens from the urethra or intraprostatic reflux of infected urine.

Men > 35 > 35 > 35 years: Coliform enteric bacilli: Escherichia coli (75–85%) , Klebsiella , Proteus , Enterobacter , Pseudomonas , and Enterococcus .

Men < 35 < 35 < 35 years (or high-risk sexual behavior): Sexually transmitted pathogens: Neisseria gonorrhoeae and Chlamydia trachomatis .

Clinical Presentation: Sudden onset of high fever, chills, rigors, malaise, severe perineal and sacral back pain, suprapubic ache, dysuria, urinary frequency, urgency, and acute obstructive voiding symptoms (hesitancy, weak stream, urinary retention).

Physical Examination:

Gentle Digital Rectal Examination (DRE) reveals a warm, swollen, exquisitely tender, tense, boggy prostate . +-----------------------------------------------------------------------------+

  • | CRITICAL CLINICAL WARNING: DO NOT MASSAGE! |
  • | |
  • | Vigorous, repeated, or aggressive prostatic massage is STRICTLY |
  • | CONTRAINDICATED in Acute Bacterial Prostatitis! |
  • | |
  • | Pathophysiological Rationale: Compressing the acutely inflamed, infected |
  • | prostate forces live uropathogens into the prostatic venous plexus and |
  • | systemic circulation, precipitating BACTEREMIA AND LIFE-THREATENING |
  • | SEPTIC SHOCK! |
  • +-----------------------------------------------------------------------------+

Management Protocol for Acute Bacterial Prostatitis:

Outpatient Mild-to-Moderate Coliform Prostatitis: Prescribe oral antibiotics with high lipid solubility and excellent prostatic tissue penetration for 4 to 6 weeks (prolonged course required to sterilize prostatic parenchyma):

Ciprofloxacin 500 mg 500\text{ mg} 500 mg PO BID × 4 – 6 weeks \times 4\text{--}6\text{ weeks} × 4 – 6 weeks , OR

Levofloxacin 500 mg 500\text{ mg} 500 mg PO daily × 4 – 6 weeks \times 4\text{--}6\text{ weeks} × 4 – 6 weeks , OR

TMP-SMX DS 1 tablet PO BID × 4 – 6 weeks \times 4\text{--}6\text{ weeks} × 4 – 6 weeks .

STI Prostatitis (Age < 35 <35 < 35 or high risk):

Ceftriaxone 500 mg 500\text{ mg} 500 mg IM single dose PLUS Doxycycline 100 mg 100\text{ mg} 100 mg PO BID × 14 days \times 14\text{ days} × 14 days .

Acute Urinary Retention: If the patient develops acute retention, transurethral Foley catheterization is contraindicated (causes severe pain and risk of prostatic parenchymal disruption/sepsis); place a percutaneous suprapubic catheter instead.

3. Epididymitis, Orchitis & Testicular Scrotal Emergencies

Acute Epididymitis is an inflammation of the epididymis resulting from retrograde ascent of pathogens from the urethra or bladder via the ejaculatory duct and vas deferens. +-----------------------------------------------------------------------------+

  • | EPIDIDYMITIS ETIOLOGY: AGE-STRATIFIED MATRIX |
  • | |
  • | AGE GROUP / POPULATION PRIMARY PATHOGENS GUIDELINE REGIMEN |
  • | ----------------------------------------------------------------------- |
  • | Men < 35 Years Chlamydia trachomatis CEFTRIAXONE 500 mg IM |
  • | (Sexually Active / STIs) Neisseria gonorrhoeae single dose |
  • | PLUS |
  • | DOXYCYCLINE 100 mg |
  • | orally BID x 10 days. |
  • | |
  • | Men >= 35 Years Escherichia coli, LEVOFLOXACIN 500 mg |
  • | (Coliform / Enteric / BPH) Pseudomonas, Klebsiella orally daily x 10 d, |
  • | OR OFLOXACIN 300 mg |
  • | orally BID x 10 days. |
  • | |
  • | Men Practicing Insertive C. trachomatis, CEFTRIAXONE 500 mg IM |
  • | Anal Intercourse N. gonorrhoeae, PLUS PLUS |
  • | Enteric Coliforms LEVOFLOXACIN 500 mg |
  • | orally daily x 10 d. |
  • +-----------------------------------------------------------------------------+
  • Clinical Differentiation: Epididymitis vs. Testicular Torsion

Testicular torsion is a surgical emergency characterized by twisting of the spermatic cord, compromising venous outflow and arterial inflow. The AGPCNP must rapidly distinguish torsion from epididymitis.

Diagnostic Feature Acute Epididymitis Testicular Torsion (SURGICAL EMERGENCY!)

Onset of Pain Gradual, insidious onset over 1–3 days. Sudden, acute, agonizing onset (minutes to hours).

Systemic Features Fever, pyuria, dysuria, urethral discharge common. Nausea and vomiting common; usually afebrile.

Testicular Position Normal vertical anatomical position; epididymis swollen posterior to testis. Elevated, high-riding, horizontal lie ("Bell-clapper deformity").

Prehn's Sign POSITIVE Prehn's Sign: Physical elevation and support of the scrotum RELIEVES PAIN . NEGATIVE Prehn's Sign: Elevation of the scrotum does NOT relieve pain (or worsens pain).

Cremasteric Reflex PRESERVED: Stroking the ipsilateral inner thigh causes elevation of the testis. ABSENT: Cremasteric reflex is abolished on the affected side.

Color Doppler Scrotal Ultrasound Increased blood flow (Hyperemia) to epididymis and testis. ABSENT or markedly decreased blood flow to affected testis.

Definitive Clinical Action Outpatient targeted antimicrobial therapy, scrotal support, NSAIDs, ice packs. IMMEDIATE UROLOGICAL SURGICAL CONSULTATION FOR DETORSION & BILATERAL ORCHIOPEXY (Viability drops precipitously after 6 hours!). +-----------------------------------------------------------------------------+

  • | PHYSICAL SIGNS IN ACUTE SCROTAL PAIN |
  • | |
  • | [ PREHN'S SIGN ] |
  • | - Technique: Examiner gently lifts the affected hemiscrotum toward pubis. |
  • | - POSITIVE (Pain decreases) -> Supports ACUTE EPIDIDYMITIS. |
  • | - NEGATIVE (Pain persists/worsens) -> Strongly suggests TESTICULAR TORSION|
  • | |
  • | [ CREMASTERIC REFLEX ] |
  • | - Technique: Stroke the superior-medial thigh with an applicator. |
  • | - Normal / Intact -> Ipsilateral cremaster muscle contracts (testis rises)|
  • | - PRESERVED -> Supports ACUTE EPIDIDYMITIS. |
  • | - ABSENT -> Pathognomonic hallmark of TESTICULAR TORSION. |
  • +-----------------------------------------------------------------------------+
  • 4. Erectile Dysfunction (ED) & Hypogonadism
  • Pathophysiology of Penile Erection

Erection is a neurovascular event initiated by sexual stimulation:

Non-Adrenergic, Non-Cholinergic (NANC) neurons and endothelial cells release Nitric Oxide (NO) into the corpus cavernosum.

NO stimulates soluble guanylyl cyclase, increasing cyclic Guanosine Monophosphate (cGMP) .

Elevated cGMP lowers intracellular calcium, producing smooth muscle relaxation in cavernosal arterioles and trabecular meshwork.

Engorgement of cavernosal lacunar spaces with blood compresses the subtunical venules against the rigid tunica albuginea, trapping blood ( veno-occlusive mechanism ).

Detumescence: Phosphodiesterase Type 5 (PDE5) hydrolyzes cGMP to 5'-GMP, leading to smooth muscle contraction and venous outflow.

Etiological Classification of ED

Vasculogenic ED (70–80% of cases): Atherosclerosis, endothelial dysfunction, hypertension, diabetes, smoking, peripheral vascular disease.

Clinical Concept: "The Artery Size Hypothesis" — Cavernosal arteries are small ( 1 – 2 mm 1\text{--}2\text{ mm} 1 – 2 mm ) compared to coronary ( 3 – 4 mm 3\text{--}4\text{ mm} 3 – 4 mm ) and carotid ( 5 – 7 mm 5\text{--}7\text{ mm} 5 – 7 mm ) vessels. Vasculogenic ED is an early surrogate marker of occult coronary artery disease (CAD), preceding acute coronary syndromes by 3 to 5 years !

Neurogenic ED: Diabetic autonomic neuropathy, radical prostatectomy (cavernosal nerve injury), spinal cord trauma, multiple sclerosis, Parkinson's disease.

Endocrine ED: Hypogonadism (low testosterone), hyperprolactinemia, hypo/hyperthyroidism.

Psychogenic ED: Performance anxiety, depression, marital conflict. Hallmark: Sudden onset, situational, with preserved nocturnal and early morning erections (which are absent in organic/vasculogenic ED).

Medication-Induced ED: Antihypertensives (Beta-blockers, Thiazide diuretics, Spironolactone), SSRIs, SNRIs, 5-ARIs, Antiandrogens, H2RAs (Cimetidine).

Diagnostic Evaluation & Testosterone Testing Protocol

Cardiovascular Risk Assessment: Stratify using the Princeton Consensus III guidelines before prescribing pro-erectile drugs or clearing for sexual activity.

Serum Testosterone Evaluation:

Testosterone exhibits significant diurnal variation (peaks in early morning).

Measure Total Serum Testosterone drawn in the fasting state between 8:00 AM and 10:00 AM .

Confirmation Rule: A low testosterone level ( < 300 ng/dL < 300\text{ ng/dL} < 300 ng/dL ) must always be confirmed with a second early morning repeat fasting sample plus Free Testosterone, serum Luteinizing Hormone (LH), Follicle-Stimulating Hormone (FSH), and Serum Prolactin to differentiate primary (testicular) from secondary (pituitary/hypothalamic) hypogonadism.

Stepwise Management of Erectile Dysfunction +-----------------------------------------------------------------------------+

  • | STEPWISE ED MANAGEMENT ALGORITHM |
  • | |
  • | STEP 1: LIFESTYLE & CARDIOVASCULAR MODIFICATION |
  • | - Smoking cessation, weight loss, exercise, glycemic/lipid control. |
  • | - Review and substitute offending medications (e.g., switch thiazide to |
  • | ACEi/ARB; switch SSRI to Bupropion). |
  • | |
  • | STEP 2: FIRST-LINE PHARMACOTHERAPY (PDE5 INHIBITORS) |
  • | - Sildenafil (Viagra): 25-100 mg PRN 1 hr before sex; duration 4-8 hr; |
  • | take on empty stomach (fatty meals delay absorption). |
  • | - Tadalafil (Cialis): 10-20 mg PRN or 2.5-5 mg daily; duration up to |
  • | 36 hours ("weekend pill"); absorption unaffected by food. |
  • | - Vardenafil (Levitra): 10-20 mg PRN; Avanafil (Stendra): rapid onset 15m.|
  • | |
  • | STEP 3: SECOND-LINE THERAPIES |
  • | - Vacuum Erection Devices (VED; constriction ring max 30 min). |
  • | - Intraurethral Alprostadil Pellets (MUSE). |
  • | - Intracavernosal Injections (ICI: Alprostadil, Trimix; risk of priapism).|
  • | |
  • | STEP 4: THIRD-LINE SURGICAL THERAPY |
  • | - Inflatable Penile Prosthesis (IPP) surgical implantation. |
  • +-----------------------------------------------------------------------------+

Caution

Lethal Drug Interaction: PDE5 Inhibitors and Nitrates: Co-administration of any PDE5 inhibitor with Nitrates (e.g., sublingual Nitroglycerin, Isosorbide mononitrate, Isosorbide dinitrate, or inhaled alkyl nitrites / "poppers") is ABSOLUTELY CONTRAINDICATED .

Mechanism: Nitrates stimulate guanylyl cyclase to produce massive amounts of cGMP, while PDE5 inhibitors block cGMP breakdown. The resulting synergistic cGMP surge triggers uncontrolled, profound vascular smooth muscle relaxation, resulting in catastrophic refractory hypotension, cardiogenic shock, and fatal cardiovascular collapse .

Safety Clearance Windows: If a patient on a PDE5 inhibitor develops acute coronary syndrome / chest pain:

Nitrates must be withheld for at least 24 hours after taking Sildenafil or Vardenafil .

Nitrates must be withheld for at least 48 hours after taking Tadalafil .